Trial reportCancer science2017
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
Trial report in Cancer science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2023Trial
- Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.Targeted oncology · 2019Trial
- Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.Cancer science · 2017Trial
- Novel agents and therapeutic advances in T cell lymphoma.International journal of hematology · 2026Review
- Article
- Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025Article
- Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma.Blood advances · 2024Article
- Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.Haematologica · 2023Article
- Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL).Frontiers in oncology · 2023Review
- Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.BMC cancer · 2021Article
- Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas.Cold Spring Harbor perspectives in medicine · 2021Review
- Pralatrexate for refractory mycosis fungoides in two Japanese patients.The Journal of dermatology · 2021Article
- Updates in the Treatment of Peripheral T-Cell Lymphomas.Journal of experimental pharmacology · 2021Review
- Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers.Genes, chromosomes & cancer · 2020Article
- Treatment approaches in relapsed or refractory peripheral T-cell lymphomas.F1000Research · 2020Review
- Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.Scientific reports · 2019Article
- Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.Frontiers in medicine · 2019Review
- Recent advances in understanding and managing T-cell lymphoma.F1000Research · 2017Review
- Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin.Case reports in oncologyArticle
- Linfoma Nasal de Células T/Natural Killer Extranodal Refractario Mal Diagnosticado, Tratado de Manera Exitosa: Informe de Caso.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or refractory peripheral T-cell lymphoma. To assess its safety, efficacy, and pharmacokinetics in Japanese patients with this disease, we undertook a phase I/II study. Pralatrexate was given i.v. weekly for 6 weeks of a 7-week cycle. All patients received concurrent vitamin B
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.